To present the benefits and clinical evidence supporting suprachoroidal space (SCS) injection as a drug delivery method for diabetic macular edema (DME).
Key Findings:
SCS injection allows for high drug concentrations in the posterior segment of the eye.
Minimizes exposure to anterior segment tissues, potentially reducing cataract risk and intraocular pressure.
Clinical evidence shows significant improvement in vision and reduced treatment frequency with SCS injection of TA.
Interpretation:
SCS injection represents a promising advancement in the management of DME, offering targeted therapy with fewer complications compared to traditional methods.
Limitations:
Further studies are needed to fully establish long-term safety and efficacy.
Limited data on the comparative effectiveness against other treatment modalities.
Conclusion:
SCS injection could refine DME management strategies, enhancing patient outcomes and reducing treatment burden.
